Clinical & Translational Immunology最新文献

筛选
英文 中文
IF 3.8 2区 医学
Clinical & Translational Immunology Pub Date : 2026-04-16
{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":152,"journal":{"name":"Clinical & Translational Immunology","volume":"15 4","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148077995","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IF 3.8 2区 医学
Clinical & Translational Immunology Pub Date : 2026-04-16
{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":152,"journal":{"name":"Clinical & Translational Immunology","volume":"15 4","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148077996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neutralising antibody responses to emerging SARS-CoV-2 omicron sub-variants are enhanced in persons with hybrid immunity. 混合免疫人群对新出现的SARS-CoV-2组粒亚变体的中和抗体反应增强。
IF 3.4 2区 医学
Clinical & Translational Immunology Pub Date : 2026-04-16 eCollection Date: 2026-01-01 DOI: 10.1002/cti2.70095
Sharon L Walmsley, Majid Nabipoor, Freda Qi, Leif Erik Lovblom, Rizani Ravindran, Karen Colwill, Anne Claude Gingras
{"title":"Neutralising antibody responses to emerging SARS-CoV-2 omicron sub-variants are enhanced in persons with hybrid immunity.","authors":"Sharon L Walmsley, Majid Nabipoor, Freda Qi, Leif Erik Lovblom, Rizani Ravindran, Karen Colwill, Anne Claude Gingras","doi":"10.1002/cti2.70095","DOIUrl":"10.1002/cti2.70095","url":null,"abstract":"<p><strong>Objectives: </strong>To assess neutralizing antibody responses to emerging SARS-CoV-2 variants.</p><p><strong>Methods: </strong>We explored SARS-CoV-2 neutralizing antibodies in140 adults participating in a longitudinal study of antibody responses to COVID vaccines. Participants reported monthly on vaccine doses, and SARS-CoV-2 infections. Serum was collected in December 2023 and April 2024 to determine neutralizing antibody to Wuhan ancestral strain and Omicron XBB.1.5 and JN.1 subvariants. Multivariate analysis assessed protective factors against a new SARS-CoV-2 infection between the two sampling times and 10 months follow up.</p><p><strong>Results: </strong>74% had hybrid immunity and 26% vaccine only immunity at study entry. A neutralizing antibody response was detected in 99% to Wuhan ancestral strain compared to 86% and 79% respectively to Omicron XBB.1.5 and JN.1 subvariants. For those with detectable antibodies the levels decayed, faster in those with vaccine only immunity and to the JN.1 subvariant. Neither the presence or the level of neutralizing antibody to JN.1 was associated with protection with a new SARS-Cov-2 infection over the 10-month follow up period.</p><p><strong>Conclusion: </strong>Neutralizing antibody levels to Omicron JN.1 subvariant were identified in 79% overall but in only 56% with vaccine only immunity. The presence or level was not associated with protection form a new SARS-CoV-2 infection over 10-months. This data supports the development of pan-coronavirus vaccine to expand protection against emerging variants.</p>","PeriodicalId":152,"journal":{"name":"Clinical & Translational Immunology","volume":"15 4","pages":"e70095"},"PeriodicalIF":3.4,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13084193/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147721095","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Seropositivity against rubella virus envelope protein 1, but not 2, is associated with an increased risk of multiple sclerosis. 风疹病毒包膜蛋白1(而非2)血清阳性与多发性硬化症风险增加有关。
IF 3.4 2区 医学
Clinical & Translational Immunology Pub Date : 2026-04-16 eCollection Date: 2026-01-01 DOI: 10.1002/cti2.70094
Jens Ingvarsson, Viktor Grut, Martin Biström, Linn Persson Berg, Julia Butt, Birgitta Michels, Pernilla Stridh, Tomas Olsson, Lars Alfredsson, Ingrid Kockum, Tim Waterboer, Staffan Nilsson, Peter Sundström
{"title":"Seropositivity against rubella virus envelope protein 1, but not 2, is associated with an increased risk of multiple sclerosis.","authors":"Jens Ingvarsson, Viktor Grut, Martin Biström, Linn Persson Berg, Julia Butt, Birgitta Michels, Pernilla Stridh, Tomas Olsson, Lars Alfredsson, Ingrid Kockum, Tim Waterboer, Staffan Nilsson, Peter Sundström","doi":"10.1002/cti2.70094","DOIUrl":"10.1002/cti2.70094","url":null,"abstract":"<p><strong>Objective: </strong>Several factors have been associated with altered risk of developing multiple sclerosis (MS). Epstein-Barr virus (EBV) is the critical risk factor for MS, but recent studies indicate that human herpesvirus 6A (HHV-6A) and cytomegalovirus (CMV) are involved in MS aetiopathogenesis. We recently reported an association between rubella virus (RV) envelope protein 1 (E1) seropositivity and the risk of developing MS. Here, we aimed to further explore this association.</p><p><strong>Methods: </strong>Bio-banked blood samples collected before the onset of MS from 981 cases and 1278 matched controls were analysed for antibodies against RV envelope proteins 1 and 2 (E2), and serum-neurofilament light chain (S-NfL), a marker for axonal injury. The association between RV and MS was analysed with conditional logistic regression, calculating odds ratios (OR) with 95% confidence intervals (CI).</p><p><strong>Results: </strong>Rubella E1 seropositivity was significantly associated with a higher risk of MS development, even when adjusting for EBV, CMV and HHV-6A serostatus (OR = 1.67, 95% CI 1.29-2.14, <i>P</i> < 0.001). We also observed an increase in seroreactivity against RV E1 before an increase in S-NfL in MS cases, indicating that increased RV E1 seroreactivity precedes axonal injury in the MS prodrome at group-level. There was no association between RV E2 serostatus and MS risk. The association between RV E1 serostatus and MS risk remained similar when the analysis was restricted to unvaccinated participants (OR = 1.78, 95% CI 1.07-2.98, <i>P</i> = 0.028).</p><p><strong>Conclusions: </strong>Our results support a broadening of the viral hypothesis in MS, arguing for further studies on the neurotropic RV in MS aetiology.</p>","PeriodicalId":152,"journal":{"name":"Clinical & Translational Immunology","volume":"15 4","pages":"e70094"},"PeriodicalIF":3.4,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13084256/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147721071","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IF 3.8 2区 医学
Clinical & Translational Immunology Pub Date : 2026-04-15
{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":152,"journal":{"name":"Clinical & Translational Immunology","volume":"15 4","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148077552","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IF 3.8 2区 医学
Clinical & Translational Immunology Pub Date : 2026-04-15
{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":152,"journal":{"name":"Clinical & Translational Immunology","volume":"15 4","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148077551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Fatty acid metabolism-an emerging regulatory node in T-cell immunometabolism. 脂肪酸代谢- t细胞免疫代谢的新兴调控节点。
IF 3.4 2区 医学
Clinical & Translational Immunology Pub Date : 2026-04-15 eCollection Date: 2026-01-01 DOI: 10.1002/cti2.70091
Brett Chapel Arenberg, Michael N Sack, Jing Wu
{"title":"Fatty acid metabolism-an emerging regulatory node in T-cell immunometabolism.","authors":"Brett Chapel Arenberg, Michael N Sack, Jing Wu","doi":"10.1002/cti2.70091","DOIUrl":"10.1002/cti2.70091","url":null,"abstract":"<p><p>While the roles of glucose metabolism and tricarboxylic acid (TCA) cycle intermediates in immune regulation are well established, the contribution of fatty acid metabolism remains less well defined. In this review, we examine current knowledge on the immunomodulatory functions of fatty acid metabolism, with a particular focus on T-cell biology. We discuss the catabolic, anabolic and signalling aspects of lipid metabolism and their influence on immune function. Short-chain fatty acids modulate T-cell epigenetics through histone acetylation, thereby impacting gene expression. Medium- and long-chain fatty acids augment fatty acid oxidation (FAO), which supports the expansion and function of regulatory T-cell populations. Very-long-chain polyunsaturated fatty acids, when cleaved from the membrane, serve as precursors for both pro-inflammatory and pro-resolving signalling molecules. Additionally, <i>de novo</i> fatty acid synthesis contributes to membrane biogenesis and alters acetyl-CoA availability, linking lipid metabolism to epigenetic regulation. The mechanisms described above present promising opportunities to modulate inflammation through targeted therapies. In this review, we focus on emerging targets within fatty acid metabolism pathways that show potential for influencing inflammatory responses in translational models. Specifically, we review key transcription factors, metabolic enzymes and dietary interventions, while also addressing current limitations and challenges in translating these findings to clinical settings. Although studies in murine models have yielded encouraging results, substantial gaps remain-particularly in applying these metabolic strategies to human T-cell biology. We conclude by emphasising the importance of validating these targets in <i>ex vivo</i> human models as a critical step towards future clinical intervention.</p>","PeriodicalId":152,"journal":{"name":"Clinical & Translational Immunology","volume":"15 4","pages":"e70091"},"PeriodicalIF":3.4,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13082870/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147696895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Spatial omics for profiling the dynamic tumor microenvironment 空间组学分析动态肿瘤微环境
IF 3.8 2区 医学
Clinical & Translational Immunology Pub Date : 2026-04-13 DOI: 10.1002/cti2.70084
Hao Nguyen, Merrin Mary Eapen, Quan Nguyen, Ankur Sharma
{"title":"Spatial omics for profiling the dynamic tumor microenvironment","authors":"Hao Nguyen,&nbsp;Merrin Mary Eapen,&nbsp;Quan Nguyen,&nbsp;Ankur Sharma","doi":"10.1002/cti2.70084","DOIUrl":"https://doi.org/10.1002/cti2.70084","url":null,"abstract":"<p>Spatial transcriptomics (ST) and spatial proteomics (SP) have revolutionised our ability to map RNA and protein distributions within intact tissues, shedding new light on the dynamic interactions that drive physiological processes in healthy and diseased tissues. We discuss how the latest ST and SP technologies, large public data resources and advanced computational pipelines can be applied to study the tumor microenvironment (TME), focussing on the interactions within the TME. We also highlight how these developments have enabled the in-depth spatial characterisation of tumors and their TME across the continuum of cancer progression, from initiation to metastasis. Despite these advances, major gaps persist in cross-platform integration, data standardisation and computational scalability for high-plex single-cell datasets. The integration of artificial intelligence (AI) holds great promise for biological and translational applications but requires standardised workflows, cost-effective pipelines, rigorous pre-clinical and clinical validation, and improved interpretability of AI models. Additional cross-disciplinary development of explainable, scalable tools for TME analysis of cellular interactions and disease progression will be essential to integrate spatial omics into daily precision cancer medicine.</p>","PeriodicalId":152,"journal":{"name":"Clinical & Translational Immunology","volume":"15 4","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cti2.70084","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147683749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IF 3.8 2区 医学
Clinical & Translational Immunology Pub Date : 2026-04-13
{"title":"","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"","PeriodicalId":152,"journal":{"name":"Clinical & Translational Immunology","volume":"15 4","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-04-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148076727","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A characterisation of the immune cells in immunocompetent and immunodeficient mice with orthotopic brain tumors 免疫正常和免疫缺陷小鼠原位脑肿瘤的免疫细胞特征。
IF 3.8 2区 医学
Clinical & Translational Immunology Pub Date : 2026-04-09 DOI: 10.1002/cti2.70093
Bryan Gardam, Eunwoo Nam, Paris M Kollis, Jasmine Kilyen-Coles, S Lenin, Briony L Gliddon, Melinda N Tea, Stuart M Pitson, Michael P Brown, Lisa M Ebert, Tessa Gargett
{"title":"A characterisation of the immune cells in immunocompetent and immunodeficient mice with orthotopic brain tumors","authors":"Bryan Gardam,&nbsp;Eunwoo Nam,&nbsp;Paris M Kollis,&nbsp;Jasmine Kilyen-Coles,&nbsp;S Lenin,&nbsp;Briony L Gliddon,&nbsp;Melinda N Tea,&nbsp;Stuart M Pitson,&nbsp;Michael P Brown,&nbsp;Lisa M Ebert,&nbsp;Tessa Gargett","doi":"10.1002/cti2.70093","DOIUrl":"10.1002/cti2.70093","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Glioblastoma is characterised by poor survival with few treatment advances for over 20 years. Immunotherapies, which have transformed treatment of other cancers, have been difficult to apply to glioblastoma because of its highly immune-suppressive microenvironment, and there is a growing appreciation that the disease also induces a global suppression of the systemic immune system. However, immunotherapy research is hampered by the lack of detailed characterisation of the whole immune system in murine brain tumor models, with studies until now having focussed mainly on tumor-infiltrating immune cells.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Here, we have studied common murine models of intracranial brain tumors by using high-parameter flow cytometry and tissue immunofluorescence staining to fully characterise immune cells in the brain, draining lymph node, spleen and bone marrow.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The highly immune-compromised NSG mouse models were striking in their many immune perturbations, which extended beyond the known deficits in lymphocytes. Immunocompetent tumor models had significant changes in brain-resident immune cells compared to controls, as expected; however, systemic effects were also observed with significant reductions in subsets of monocytes, macrophages and dendritic cells in the spleen and increases in bone marrow.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our extensive and quantitative characterisation of the immune system in murine models of glioblastoma will allow for a better-informed selection of models and advance the search for new immune-based treatments for this deadly disease.</p>\u0000 </section>\u0000 </div>","PeriodicalId":152,"journal":{"name":"Clinical & Translational Immunology","volume":"15 4","pages":""},"PeriodicalIF":3.8,"publicationDate":"2026-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13065875/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147669318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书